Archived News & Press Releases

	2008
	2007
	2006
	2005

December 12, 2008 - Perceptronix to Exhibit at Vancouver District and Dental Society Annual MidWinter Clinic [PDF]
Vancouver, BC, December 11, 08 – Perceptronix will be exhibiting at the Vancouver and District Dental Society Annual MidWinter Clinic on December 12, 2008 at the Westin Bayshore Resort & Marina in Vancouver. Perceptronix will be showcasing OralAdvance™, a new quantitative cytology test for the early detection of oral cancer, and demonstrating its use at booth 58.

November 17, 2008 - Perceptronix to Exhibit at St. Paul's Hospital CME Conference [PDF]
Vancouver, BC, November 17, 08 – Perceptronix Medical Inc. will be exhibiting at the St. Paul's Hospital Annual Continuing Medical Education Conference from November 18 - 21. Perceptronix will be showcasing LungSign™, an innovative early lung cancer test currently available for lung cancer risk assessment, as well as premiering an instructional video demonstrating its use. The company will be exhibiting at booth 127 at the Vancouver Convention & Exhibition Centre.

November 13, 2008 - Perceptronix to Exhibit at Toronto Academy of Dentistry Annual Winter Clinic [PDF]
Vancouver, BC, November 13, 08 – Perceptronix Medical Inc., an independent quantitative cytology laboratory specializing in early cancer detection tests, will be exhibiting at the Toronto Academy of Dentistry's 71st Annual Winter Clinic on November 14, 2008 at the Metro Toronto Convention Centre. Perceptronix will be showcasing OralAdvance™, a new quantitative cytology test for the early detection of oral cancer, and demonstrating its use at booth 1112.

November 10, 2008 - LungSign™ Study to Monitor Lung Cancer Recurrence [PDF]
Vancouver, BC, November 10, 08 – In this month of international Lung Cancer Awareness, Perceptronix Medical Inc. (Perceptronix) is pleased to announce the initiation of a new, longitudinal study with the Respiratory Department of Saint Paul's Hospital (Vancouver, Canada). Dr. Pearce Wilcox, MD, FRCP and his team will evaluate the use of LungSign™ in monitoring for recurrence in subjects with recently re-sected lung cancer. Recurrence rate for lung cancer after resection can be in range from 5% to 15% thus early detection of recurrence among these patients could save many lives.

October 22, 2008 - Perceptronix to Exhibit at Canadian Association of General Practitioners in Oncology [PDF]
Vancouver, BC, October 22, 08 – Perceptronix Medical Inc., an independent quantitative cytology laboratory specializing in early cancer diagnosis, is honoured to be a bronze sponsor for the Canadian Association of General Practitioners In Oncology (CAGPO) Annual Conference. The company will be exhibiting at booth 15 during the CAGPO meeting from October 24 - 26, 2008 in Kelowna, BC. Perceptronix, along with distribution partner Independent Respiratory Servics Inc., will be showcasing LungSign™, an innovative early lung cancer test currently available for lung cancer risk assessment.

October 22, 2008 - Perceptronix to Exhibit at Thompson Okanagan Dental Meeting [PDF]
Vancouver, BC, October 22, 08 – Perceptronix Medical Inc., an independent quantitative cytology laboratory specializing in early cancer diagnosis, will be exhibiting at the Thompson Okanagan Dental Meeting on October 24, 2008 in Kelowna, Canada. Perceptronix will be showcasing OralAdvance™, the first quantitative cytology test for the early detection of oral cancer, as well as demonstrating how to use the cyto-brush sample collection kit at booth 52.

September 30, 2008 - Perceptronix to Present at BioContact Québec [PDF]
Vancouver, BC, September 30, 08 – Perceptronix Medical Inc., a privately owned independent cytology laboratory specializing in early cancer detection tests, will present at the BioContact biopharmaceutical partnership symposium at Château Frontenac in Québec City. The symposium will be held on October 2nd, 2008, at 2pm, Salle Petit Frontenac. Dr. Bojana Turic, President and CEO of Perceptronix will provide the Company overview and its' newest development and business strategies.

June 24, 2008 - Perceptronix Signs Significant Partnership Agreements for Early Lung Cancer Detection Test, LungSignT [PDF]
Vancouver, BC, June 24, 08 – Perceptronix is pleased to announce two (2) new distribution partnerships signifying an important third party validation of LungSign™ and its value in the market place. IRS (Independent Respiratory Services) and Medpro Respiratory Care have agreed to add the LungSignT test kit to their list of offerings allowing physicians to now order the test directly through these service providers. Patients will receive a test kit, with a physician's requisition, from our distributors' office in their geographic area and then mail the specimen to the Perceptronix' laboratory for analysis.

CTV News - British Columbia
June 04, 2008
"New lung cancer screening test now in Canada" - featured by CTV British Columbia's Dr. Rhonda Low.

May 16 , 2008 - Early Detection Brings Hope [PDF]
Vancouver, BC, May 16, 08 –”Early detection of any cancer is always the best hope for successful treatment and a positive outcome, but early detection for lung cancer has never been more important than now,” says Bojana Turic, MD, president and CEO of Perceptonix Medical Inc., Vancouver, “when on average 388 Canadians will die of lung cancer every week.“

March 7, 2008 - New Perceptronix Medical Inc. test for early-stage oral cancer demonstrated at Pacific Dental Conference [PDF]
Vancouver, BC, March 7, 08 – "Early diagnosis is the most effective way of controlling cancer, and improving the quality of life for patients," says Dr. Bojana Turic, President and CEO of Perceptronix. "Our tests apply advanced automated image cytometry to analyze and evaluate changes in epithelial cells indicative of cancer. The results of early detection tests complement recognized standards of care, enabling timely treatment and encouraging a positive outcome."

February 1 , 2008 - Perceptronix featured at BioPartnering North America [PDF]
Vancouver, BC, February 1, 08 – Perceptronix Medical Inc. (Perceptronix) is pleased to announce its participation at the 6th Annual BioPartnering North America conference, February 3-5, 2008 at the Westin Bayshore in Vancouver, BC. Not only will Perceptronix be represented on the exhibiting floor (Monday, February 4th, 9:45 - 11:45 am) but Dr. Bojana Turic will also highlight Perceptronix' recent developments during her presentation at 3:30 pm the same day.

January 29 , 2008 - Kelowna Figures Prominently in Lung Cancer Research [PDF]
Vancouver, BC, January 29, 08 – Perceptronix Medical Inc. (Perceptronix) was pleased to return to Kelowna, BC on January 24, 2008 to host a special meeting featuring the positive results of an international, multi-centre clinical study for lung cancer in which participants from Kelowna played a significant role.

November 13 , 2007 - Perceptronix to Exhibit at MEDICA 2007 [PDF]
Düsseldorf, Germany, November 13, 07 – As part of their continuing commitment to improving cancer outcomes through earlier detection, Perceptronix Medical Inc. (Perceptronix) will be exhibiting at MEDICA 2007 from November 14 to 17 in Düsseldorf, Germany. Perceptronix will join fellow Canadian companies in the national pavilion (Canada in Hall 3 - Stand 3D64) showcasing the most innovative medical devices our country has to offer to a global audience.

November 8 , 2007 - Perceptronix' Scientists Publish Paper in Journal of Thoracic Oncology [PDF]
Vancouver, BC, November 8, 07 – Perceptronix Medical Inc. (Perceptronix) is pleased to report positive study results from their LungSign™ test for early detection of Lung Cancer. The study, 'Detection of Lung Cancer by Automated Sputum Cytometry' was published in the November 2007 issue of the prestigious Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC).

November 1 , 2007 - Perceptronix Announces Completion of ClearVu ELITE™ Clinical Study [PDF]
Vancouver, BC, November 1, 07 – Perceptronix Medical Inc. (Perceptronix) announced today the completion of their clinical study entitled "Spectral Imaging of Early Lung Cancer and Pre-cancerous Lesions" using the Company's ClearVu EliteT system.

Medical Acoustics LLC
September 27, 2007 by Medical Acoustics LLC
"Medical Acoustics Reports Initial Commercial Shipments of Revolutionary Lung Flute." "Perceptronix Medical Inc. to Incorporate Lung Flute (R) into its lung cancer diagnostic test, LungSign (TM) "

September 10 , 2007 - Perceptronix announces launch of LungSign™ [PDF]
Vancouver, BC, September 10, 07 – Perceptronix Medical Inc. (Perceptronix) invited local physicians to an informational symposium on Early Detection in Lung Cancer which introduced LungSign™, their product for the early detection of lung cancer, held September 5, 2007 at the Vancouver Art Gallery.

September 2, 2007 - Perceptronix to present clinical trial results at 12th World Conference on Lung Cancer [PDF]
Vancouver, BC, September 2, 07 – Perceptronix Medical Inc. (Perceptronix) announced today they will present results from their clinical trial of LungSign™ at the 12th World Conference on Lung Cancer being held in Seoul, Korea September 2-6, 2007. Dr. David Snead, Consultant Pathologist at Walsgrave NHS Trust Hospital Coventry UK, will introduce the data during his oral presentation scheduled for September 2nd.

June 11, 2007 - Perceptronix selected to present at international forum promoting interdisciplinary collaborations [PDF]
Vancouver, Canada (June 11, 2007) – Dr. Bojana Turic, President and CEO, Perceptronix Medical Inc. (“Perceptronix”) will present at BioDevice Partnering on June 13 at Technopark in Zurich, Switzerland. Dr. Turic would like to invite all those interested in innovative technologies and services for the early detection of cancer to attend her presentation.

June 7, 2007 - Perceptronix launches LungSign.com: providing exciting information on innovative technology that brings new hope to those at risk for lung cancer [PDF]
Vancouver, Canada (June 6, 2007) – Perceptronix Medical Inc. (“Perceptronix”), a private biotechnology company focused on detecting cancer at early stages, is pleased to announce the launch of its new website, www.lungsign.com. LungSign.com is designed to be a primary resource for patients and healthcare providers interested in the early detection of lung cancer.

cCoventry - Midland Newspapers
May 30, 2007 by Sinead Keller
"Life-saver cancer test launched - Thousands of people in Coventry could get early lung cancer detection, thanks to a pioneering move by the city's superhospital."

May 28, 2007 - Perceptronix brings early lung cancer detection to UK by signing service agreement with University Hospital of Coventry and Warwickshire NHS Trust [PDF]
Vancouver, Canada (May 28, 2007) – Perceptronix Medical Inc. (“Perceptronix”) announced it has signed a service agreement for its LungSign™ test (formerly ClearSignTM) with University Hospital of Coventry and Warwickshire (UHCW) NHS Trust in the UK.

April 30, 2007 - Perceptronix invited to present at international conference: Mobilizing the Private Sector for Global Health Development [PDF]
Toronto, Canada (April 30, 2007) – Dr. Bojana Turic, President and CEO, Perceptronix Medical Inc. (“Perceptronix”) has been invited to present at the International Biotechnology Partnership Conference: Mobilizing the Private Sector for Global Health Development on May 2 at the MaRS Centre, Toronto, Ontario. Dr. Turic’s presentation will focus on the company’s approach to addressing the impact smoking-induced cancers are having in developing countries.

April 24, 2007 - Perceptronix appoints Dr. Bojana Turic as new President and Chief Executive Officer [PDF]
Vancouver, Canada (April 24, 2007) – Perceptronix Medical Inc. (“Perceptronix”) announced today that Mr. Carl F. Roy has resigned as President and Chief Executive Officer, effective immediately.  The Board of Directors has appointed Dr. Bojana Turic, MD, Vice President and Chief Operating Officer of Perceptronix, as President and Chief Executive Officer, effectively immediately.

March 14, 2007 - Perceptronix to present at Invest Northwest CEO & Investor Forum [PDF]
Seattle, USA (March 20, 2007) – Dr. Bojana Turic, Vice President, COO will present on behalf of Perceptronix Medical Inc. (“Perceptronix”) at the Invest Northwest CEO & Investor Forum on March 20 at Bell Harbor International Conference Center, Seattle, Washington. 

January 30, 2007 - Perceptronix collaborates with BC Cancer Agency on early oral cancer detection project [PDF]
Vancouver, Canada (January 30, 2007) – Perceptronix Medical Inc. (“Perceptronix”) today announced its participation in a research project to detect early oral cancer lesions through a new initiative inside the BC Oral Cancer Prevention Program. This Program is bringing together a network of dentists, researchers and technology companies to develop early screening programs for oral cancer.

January 19, 2007 - Perceptronix appoints Ms. Rohini Hira, Vice President Sales and Marketing [PDF]
Vancouver, Canada (January 19, 2007) – Perceptronix CEO Carl Roy announced the appointment of Ms. Rohini Hira to the position of Vice President Sales and Marketing effective December 15th, 2006. Ms. Hira has the vision and experience to commercialize Perceptronix’s early cancer detection products and services in Canada, the US and the EU.

December 4, 2006 - Perceptronix's first ClearSign™ lung cancer testing facility [PDF]
Vancouver, Canada (December 4, 2006) – Perceptronix Medical Inc. (“Perceptronix”) announced today that it has opened its first sputum induction facility at MDS Metro Laboratory Services’ Victoria Drive Patient Service Centre in Vancouver. This facility will be the first centre to offer sputum induction for Perceptronix’s ClearSign™ Sputum Test (“ClearSign™”).

Business in Vancouver  [PDF]
November 14-20, 2006 by Daniela Tuchel
"Private Matters - New Perceptronix CEO Carl Roy has jumped from the public sector into private enterprise to help the Vancouver biotech fight cancer and turn a profit in the bargain."

September 27, 2006 - Perceptronix attracts high profile President and CEO [PDF]
Vancouver, Canada (August 21, 2006) – The Board of Directors of Perceptronix Medical Inc. (“Perceptronix”) is pleased to announce the appointment of Mr. Carl F. Roy to the position of President and CEO, effective September 25, 2006.

August 21, 2006 - Perceptronix receives Health Canada License for early lung cancer test [PDF]
Vancouver, Canada (August 21, 2006) – Perceptronix Medical Inc. (“Perceptronix”)
announced today that it has been issued a Class III in vitro Diagnostic Device License from Health Canada for its ClearSign™ Sputum Test for the detection of early lung cancer.  Perceptronix can now market this test service in Canada as well as in the European Union, having received CE Mark registration in May, 2006.

August 14, 2006 - Perceptronix signs Contribution Agreement with National Research Council Canada [PDF]
Vancouver, Canada (August 14, 2006) – Perceptronix Medical Inc. (“Perceptronix”)
announced today that the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) has agreed to provide a financial contribution in support of the development of its ClearVu™ Elite advanced fluorescence bronchoscopy system.

June 20, 2006 - Perceptronix raises CDN$5.5M  [PDF]
Vancouver, Canada (June 20, 2006) – Perceptronix Medical Inc. (“Perceptronix”), a Vancouver based cancer diagnostics company, announced today that it has recently raised CDN$5.5 M in private financing designed to serve as a bridge to an anticipated larger institutional private placement financing. 

May 26, 2006 - Perceptronix receives CE Mark for its ClearSign™ Sputum Test for early lung cancer  [PDF]
Vancouver, Canada (May 26, 2006) – Perceptronix Medical Inc. (“Perceptronix”) announces receipt of C Mark for its ClearSign™ Sputum Test for the detection of early lung cancer, allowing it to be marketed in the European Union.
 
April 4, 2006 - Perceptronix receives US Food and Drug Administration Medical Device Listing and CE Mark for Clear2C™  [PDF]
Vancouver, Canada (April 4, 2006) - Perceptronix Medical Inc. (“Perceptronix”) announced today that it has been issued a Medical Device Listing from the US Food and Drug Administration (FDA) and CE Mark for its Clear2C™ Quantitative DNA Staining Kit. Perceptronix will now begin marketing and selling this product to all laboratories requiring consistent quantitative absorbance microscopy staining in the United States, Canada, and the European Union (EU) .
 
March 30, 2006 - Perceptronix announces the opening of its first Clinical Quantitative Cytology Lab  [PDF]
Vancouver, Canada (March 30, 2006) - Perceptronix Medical Inc. ("Perceptronix") announced today the opening of its first Quantitative Cytology Laboratory in Vancouver, British Columbia, offering advanced quantitative clinical laboratory services to assist clinicians in the diagnosis and prognosis of cancer. 

February 8, 2006 - Perceptronix receives Medical Device Licenses for ClearCyte™ and Clear2C™ from Health Canada  [PDF]
Vancouver, Canada (February 8, 2006)– Perceptronix Medical Inc ("Perceptronix") announced today that it has been issued Medical Device Licenses from Health Canada for its first two products - the ClearCyte™ Quantitative Cytology System and its associated Clear2C™ Quantitative DNA Staining Kit. Perceptronix can now market these two products in Canada.
 
February 2, 2006 - Perceptronix receives CE Mark for its first product  [PDF]
Vancouver, Canada (February 2, 2006)– Perceptronix Medical Inc ("Perceptronix") announced today that it has received CE Mark for its first product – the ClearCyte™ Quantitative Pathology System, allowing it to be marketed throughout the European Union (EU).
 
January 23, 2006 - Perceptronix Commissions United Kingdom Site of International Lung Cancer DetectionTrial  [PDF]
Vancouver, Canada (January 23, 2006)– Perceptronix Medical Inc ("Perceptronix") announced today the initiation of the Coventry site to their clinical study for the ClearVuElite™ fluorescence endoscopy system for the early detection of lung cancer, raising the total trial sites to four, including; St. Petersburg Russia, Ljubljana, Slovenia and Vancouver, Canada.

December 6, 2005 - Perceptronix announces appointment of New Directors  [PDF]
Vancouver, Canada (December 6, 2005)– Perceptronix Medical Inc ("Perceptronix") announced today the resignation of one member of its Board of Directors and the addition of two new members to its Board of Directors, brining the total Board membership to six.  

CTV News
CTV News recently featured ClearSign™ buccal in "Your Health with Dr. Rhonda Low."

October 25, 2005 - Perceptronix to present lung cancer detection test clinical trial results at international conference "CHEST 2005"  [PDF]
Vancouver, Canada (October 25, 2005)– Dr. Bojana Turic and Dr. Roger Kemp of Perceptronix Medical Inc. (“Perceptronix”) will each present a paper on the detection of lung cancer by cytometric analysis at “CHEST 2005”, the 71st annual international scientific assembly of the American College of Chest Physicians being held October 29 through November 3 in Montréal, Québec, Canada.
 
August 26, 2005 - Perceptronix announces appointment of Stephen Anderson as Chief Financial Officer.  [PDF]
Vancouver, Canada (August 26, 2005) – Perceptronix Medical Inc. (“Perceptronix”), a cancer diagnostics medical device company, announced today the appointment of Stephen Anderson as Chief Financial Officer. Mr. Anderson’s experience
includes over five years with Westport Innovations Inc. spanning roles as Controller, Vice President, Finance and Chief Financial Officer.
 
August 25, 2005 - Perceptronix announces that results of lung cancer detection test clinical trial meet test objectives  [PDF]
Vancouver, Canada (August 25, 2005) - Perceptronix Medical Inc. (“Perceptronix”) announced today that it has unblinded its clinical trial for the ClearSign™ Test, a non-invasive test for the detection of lung cancer based on the automated cytometric analysis of sputum.  Initial analysis indicates that the clinical trial met all significant objectives and the Company is optimistic that licenses will be issued for the ClearSign™ Test early in 2006.
 
July 21, 2005 - Perceptronix receives ISO (International Organization for Standardization) quality certification. Critical requirement for obtaining licenses for product sales in Canada and Internationally.  [PDF]
Vancouver, Canada (July 21, 2005) – Perceptronix Medical Inc. (“Perceptronix”), a cancer diagnostics medical device company, is proud to announce that it has received ISO 13485:2003 and ISO 9001:2000 certification of its quality management system for the “Design and manufacture of in vitro devices for the detection, localization and diagnosis of cancer”.  
 
July 19, 2005 - Perceptronix granted another U.S. patent for lung cancer detection technology. New technique could reduce number of negative biopsies.  [PDF]
Vancouver, Canada (July 19, 2005) – Perceptronix Medical Inc. (“Perceptronix”) announced today that it has been granted patent number 6,898,458 by the United States Patent and Trademark Office, entitled; “Methods and apparatus for fluorescence and reflectance imaging and spectroscopy and for contemporaneous measurement of electromagnetic radiation with multiple measuring devices”. 
 
June 7, 2005 - Perceptronix announces election of Board of Directors.  [PDF]
Vancouver, Canada (June 7, 2005) – Perceptronix Medical Inc. (“Perceptronix”) announced today the retirement of Mr. Randall Mullan (Head of Direct Investment, British Columbia Investment Management Corporation) from its Board of Directors, the election of three new members and the re-election of three previous members to its Board at its recent Annual General Meeting of Shareholders. This brings the total Board membership to six.
 
April 20, 2005 - Asia-based manufacturing partner invests in Perceptronix.  [PDF]Vancouver, Canada, 20 April, 2005 – Perceptronix Medical Inc. (“Perceptronix”), a Vancouver-based medical device company focused on cancer diagnostics, announced today that it has closed the private placement with Speed Fair Co. Ltd. ("Speed Fair") of Hong Kong referred to in its press release of 7 April, 2005.

Business in Vancouver  [PDF]
April 19-25, 2005 by Glenn Drexhage
"Vancouver biotechs take aim at lung cancer. Perceptronix Medical Inc. and Protox Therapeutics Inc. look to China and licensing opportunities for their products in the fight against the deadly disease."

April 7, 2005 - Cancer diagnostics device firm Perceptronix strengthens strategic alliance with Asia-based manufacturing partner.  [PDF]
Vancouver, Canada, 7 April, 2005 – Perceptronix Medical Inc. (“Perceptronix”), a Vancouver-based medical device company focused on cancer diagnostics, announced today that it has signed a Supply Agreement with Speed Fair Co. Ltd. (“Speed Fair”) of Hong Kong.  The signing of the Supply Agreement was the last outstanding condition for the completion of an equity investment in Perceptronix by Speed Fair. ...
 
February 18, 2005 - Perceptronix earns US patent for lung cancer detection technology.  [PDF]
Vancouver, Canada, 18 February, 2005 – Perceptronix Medical Inc. (“Perceptronix”) today announced that the United States Patent and Trademark Office has granted to Perceptronix patent number 6,826,424 entitled “Methods and apparatus for fluorescence and reflectance imaging and spectroscopy and for contemporaneous measurement ...
 
January 24, 2005 - Local cancer diagnostics firm signs agreement with China-based firm during Team Canada Trade Mission.  [PDF]
Vancouver, Canada, 24 January, 2005 – Perceptronix Medical Inc. (“Perceptronix”) announced today that it has signed a Memorandum of Understanding (“MOU”) with Speed Fair Co. Ltd. (“Speed Fair”) as part of the Hong Kong contract signing ceremony of the Prime Minister’s Team Canada Trade Mission to the People’s Republic of China.